Following an announcement in November that Venn Life Sciences was to join London’s Junior Market, the clinical trial business has completed its listing.
In doing so it has raised £2.5 million through the issue of 8,333,333 new ordinary shares at 30 pence each from institutional investors.
Venn Life Sciences is a clinical research organisation which provides consulting and clinical trial services to pharmaceutical, biotechnology and medical device companies. It has its main bases in France, the Netherlands and Ireland and a branch office in Switzerland.
Prior to joining AIM, it was listed on the ICAP Securities & Derivatives Exchange – a platform which used to be PLUS-SX.
Tony Richardson, proposed CEO of Venn Life Sciences, comments, ‘Moving to AIM is the first step in our strategy to build a mid-sized pan-European CRO.
‘We expect to achieve this through organic growth but also by targeting the acquisition of smaller, profitable regional European CRO’s to complement our existing geographies.’